These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28860784)

  • 41. Intravenous Maxacalcitol Therapy Correlates with Serum Fibroblast Growth Factor 23 Levels in Hemodialysis Patients Independent of Serum Phosphate or Calcium Levels.
    Ohya M; Yashiro M; Sonou T; Okuda K; Tatsuta K; Mima T; Tone Y; Negi S; Saika Y; Shigematsu T
    Contrib Nephrol; 2018; 196():44-51. PubMed ID: 30041203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study.
    Fusaro M; Cianciolo G; Tripepi G; Plebani M; Aghi A; Politi C; Zaninotto M; Nickolas TL; Ferrari S; Ketteler M; La Manna G; Gasperoni L; Messa P; Ravera M; Gallieni M; Cosmai L; Locatelli F; Iervasi G; Vettor R; Mereu MC; Sella S; Arcidiacono G; Giannini S
    J Bone Miner Res; 2021 Dec; 36(12):2361-2370. PubMed ID: 34622481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
    Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
    J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: its important role in serum phosphate regulation.
    Yamashita H; Yamazaki Y; Hasegawa H; Yamashita T; Fukumoto S; Shigematsu T; Kazama JJ; Fukagawa M; Noguchi S
    Endocr J; 2007 Jun; 54(3):465-70. PubMed ID: 17464094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde.
    Cianciolo G; Cozzolino M
    Clin Kidney J; 2016 Oct; 9(5):665-8. PubMed ID: 27679712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
    Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
    Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of vitamin D replacement therapy in serum FGF23 concentration in children with myelomeningocele compared with healthy children - a preliminary study.
    Bagińska J; Liszewska A; Korzeniecka-Kozerska A
    J Pediatr Endocrinol Metab; 2019 Nov; 32(11):1259-1264. PubMed ID: 31465293
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation.
    Ureña Torres PA; Souberbielle JC; Solal MC
    Metabolites; 2022 Mar; 12(3):. PubMed ID: 35323709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
    Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
    Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
    Gonzalez-Parra E; Gonzalez-Casaus ML; Galán A; Martinez-Calero A; Navas V; Rodriguez M; Ortiz A
    Nephrol Dial Transplant; 2011 Aug; 26(8):2567-71. PubMed ID: 21436379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.
    Daryadel A; Bettoni C; Haider T; Imenez Silva PH; Schnitzbauer U; Pastor-Arroyo EM; Wenger RH; Gassmann M; Wagner CA
    Pflugers Arch; 2018 Oct; 470(10):1569-1582. PubMed ID: 29961920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interventions for bone disease in children with chronic kidney disease.
    Geary DF; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2010 Jan; (1):CD008327. PubMed ID: 20091666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FGF23 as a calciotropic hormone.
    Rodríguez-Ortiz ME; Rodríguez M
    F1000Res; 2015; 4():. PubMed ID: 27081473
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: a role for FGF23.
    Mazzaferro S; Pasquali M; Pugliese F; Citterio F; Gargiulo A; Rotondi S; Tartaglione L; Conte C; Pirrò G; Taggi F
    J Nephrol; 2012; 25(6):1108-18. PubMed ID: 22383345
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T; Ritz E; Passlick-Deetjen J
    Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study.
    Liu D; Alvarez-Elías AC; Wile B; Belostotsky V; Filler G
    BMC Nephrol; 2017 Jun; 18(1):204. PubMed ID: 28659167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.